<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517697</url>
  </required_header>
  <id_info>
    <org_study_id>PRO15050540</org_study_id>
    <nct_id>NCT02517697</nct_id>
  </id_info>
  <brief_title>Oral Nitrite Trial for Hypertension and Metabolic Syndrome</brief_title>
  <acronym>ONPC</acronym>
  <official_title>Nitrite Modulation of Hypertension, Platelet Activation, and Endothelial and Mitochondrial Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gladwin, Mark, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate effects of inorganic sodium nitrite on the&#xD;
      cardiometabolic and hormonal disturbances observed in a targeted population of&#xD;
      overweight/obese adults with metabolic syndrome and hypertension, at risk for insulin&#xD;
      resistance and endothelial dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease remains the leading cause of death in the United States and worldwide.&#xD;
      Several studies have demonstrated that fruit and vegetable rich diets significantly reduced&#xD;
      blood pressure and reduced the risk of ischemic stroke and cardiovascular disease in general,&#xD;
      the exact mechanisms remain poorly understood. Preclinical and clinical research over the&#xD;
      last decade has revealed the important vasoprotective effects of nitrates and nitrites with&#xD;
      regards to reduction in blood pressure, vascular inflammation and endothelial dysfunction.&#xD;
      More recent findings suggest that inorganic nitrate and nitrite therapy may be involved in&#xD;
      the regulation of glucose-insulin homeostasis.&#xD;
&#xD;
      For this reason, development of an oral formulation of nitrite salt represents a rational&#xD;
      avenue of exploration for the treatment of cardiovascular diseases, whereby nitrite would&#xD;
      ensure rapid acting effects upon absorption. Nitrite could then be oxidized to nitrate via&#xD;
      the enterosalivary circulation pathway. In this pathway, about 25% of circulating nitrate is&#xD;
      concentrated in the saliva and reduced to nitrite by commensal mouth bacteria with nitrate&#xD;
      reductase enzymes. The proposal will investigate the inorganic nitrite effects (in any form)&#xD;
      on insulin sensitivity in a targeted population of overweight/obese adults with metabolic&#xD;
      syndrome and hypertension, at risk for insulin resistance and endothelial dysfunction. This&#xD;
      will be the third human trial using orally delivered nitrite (previously as aqueous&#xD;
      solution).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We will not initiate recruitment for this protocol due to lack of funding to support this&#xD;
    placebo-controlled trial.&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Actual">April 13, 2021</completion_date>
  <primary_completion_date type="Actual">April 13, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in insulin sensitivity (i.e. insulin stimulated glucose disposal)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>obtained by hyperinsulinemic euglycemic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>ambulatory blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean arterial pressure</measure>
    <time_frame>baseline and then biweekly throughout the 12 week treatment</time_frame>
    <description>ambulatory blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>ambulatory blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in methemoglobin level</measure>
    <time_frame>baseline and then biweekly throughout the 12 week treatment</time_frame>
    <description>by co-oximetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Active drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsules three time daily (TID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14 Nitrogen (N) Sodium Nitrite</intervention_name>
    <description>oral formulation of sodium nitrite 40 mg three times daily for 12 weeks</description>
    <arm_group_label>Active drug</arm_group_label>
    <other_name>sodium nitrite</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral formulation of matching placebo three times daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60 years&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 30 kg/m2&#xD;
&#xD;
          -  Hypertension: defined as systolic blood pressure ≥130 and/or diastolic blood pressure&#xD;
             ≥85 mm Hg&#xD;
&#xD;
          -  Waist circumference: &gt;102 cm in men, &gt;88 cm in women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive urine pregnancy test or breastfeeding&#xD;
&#xD;
          -  Concurrent use of medications affecting glucose metabolism (oral hypoglycemics,&#xD;
             insulin, atypical antipsychotics)&#xD;
&#xD;
          -  Recent addition or change in dosing of hormonal contraceptive medications (Oral&#xD;
             Contraceptive Pill (OCP), Intra Uterine Device (IUD), DepoProvera shot)&#xD;
&#xD;
          -  Current use of ≥3 anti-hypertensive agents regardless of blood pressure control or&#xD;
             normotensive on a single or double agent&#xD;
&#xD;
          -  Current use of phosphodiesterase-5 (PD) inhibitors or organic nitrates. We will not&#xD;
             exclude for dietary sources of nitrate/nitrite.&#xD;
&#xD;
          -  Not stable on treatments for the prior three months or not planning to remain on&#xD;
             current dose of medications for blood pressure, contraception, etc.&#xD;
&#xD;
          -  Known chronic psychiatric or medical conditions including diabetes, liver or kidney&#xD;
             disease or obesity syndromes&#xD;
&#xD;
          -  Thyroid Stimulating Hormone (TSH) &gt;8 milli-International unit/mL&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Anemia (central lab hemoglobin &lt; 11g/dL)&#xD;
&#xD;
          -  Active periodontal disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara S Hughan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Gladwin, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Kara S Hughan, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

